Mr. Rajnish Ohri reports

TILRAY MEDICAL ANNOUNCES MAJOR EXPANSION OF MEDICAL CANNABIS PORTFOLIO IN AUSTRALIA

Tilray Medical, a recognized global leader in medical cannabis and a division of Tilray Brands Inc., has made its largest portfolio expansion in Australia to date. The expanded medical cannabis offering reinforces Tilray Medical's long-term commitment to the Australian market and supports increased patient access to regulated, clinically supported medical cannabis products.

Tilray Medical has operated in Australia for several years, supplying EU-GMP certified medical cannabis through established prescriber, pharmacy and clinical distribution channels. This latest expansion represents a scaled increase in Tilray's local portfolio aligned with rising demand across Australia's regulated medical system and Tilray's continued commitment to supply reliable and compliant medical cannabis.

Rajnish Ohri, president, international, Tilray Brands, stated: "Australia represents an important strategic market within our international growth strategy. This launch reflects our long-term commitment to delivering quality, differentiated cannabis products."

Mr. Ohri continued: "By bringing together proven genetics, rigorous quality standards and our strong local market expertise, we are excited to support the evolving needs of the Australian community. This milestone reflects our continued investment across priority global markets, as we broaden access to trusted cannabis products worldwide."

Expanded medical cannabis portfolio across multiple formats

Over the coming months, Tilray Medical Australia will expand its medical cannabis portfolio with the introduction of new products across multiple formats under its Redecan and Good Supply brands, further enhancing treatment options for health care professionals and patients. The Redecan portfolio will include medical cannabis flower, extracts, vapes and pastilles, while Good Supply will introduce new medical cannabis flower offerings, broadening access to high-potency, patient-focused medical cannabis solutions.

Tilray Medical continues to be a leading global provider of pharmaceutical-grade medical cannabis, supplying regulated medical markets across Europe, North America and Australia. Through continuing investment in education, product stewardship and compliant supply pathways, Tilray Medical remains focused on supporting safe, consistent access for patients worldwide.

About Tilray Medical

Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray, Aphria, Broken Coast, Symbios and Navcora. Tilray grew from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first good-manufacturing-practice-certified cannabis production facilities in Europe, first in Portugal and later in Germany. Today, Tilray Medical is one of the largest suppliers of medical cannabis to patients, physicians, hospitals, pharmacies, researchers and governments, in 20 countries and across five continents.

We seek Safe Harbor.